» Articles » PMID: 30430295

Variations in the Eicosapentaenoic Acid-arachidonic Acid Ratio Associated with Age in Acute Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

Overview
Journal Heart Vessels
Date 2018 Nov 16
PMID 30430295
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myocardial infarction (AMI) is a life-threatening disease, and its incidence has been increasing even in the young population. Although a low eicosapentaenoic acid (EPA)-arachidonic acid (AA) ratio is associated with an increased risk of coronary artery disease, the effect of age on EPA/AA ratios in AMI patients remains unclear. This study aimed to clarify the independent polyunsaturated fatty acid (PUFA)-related determinants of age in younger and older AMI patients. A total of 153 consecutive patients who underwent primary percutaneous coronary interventions (PCIs) for de novo AMIs were enrolled in this study. Patients' background data, including PUFA and lipid profiles during PCI, were evaluated retrospectively. The EPA/AA ratio correlated positively with age (r = 0.21; P = 0.011) and increased markedly from age 60 years. Patients aged < 60 years (n = 35) had a lower mean EPA/AA ratio (0.25 ± 0.16) than patients aged ≥ 60 years (n = 118) (0.38 ± 0.25) (P < 0.001). The AA level was more dependent on age than on EPA level (r = - 0.34, P < 0.001 vs. r = 0.12, P = 0.16). The multivariate analysis revealed that a 0.1 EPA/AA ratio increase (odds ratio 1.50; 95% confidence interval 1.09-2.06), body mass index, triglyceride level, and aspirin administration were independently associated with the age stratification of AMI patients. The EPA/AA ratio was higher in younger AMI patients who have undergone primary PCIs than in older patients. Younger population at risk for AMI should be managed with multiple interventions including PUFA profiling.

Citing Articles

The Influence of Eicosapentaenoic Acid to Arachidonic Acid Ratio on Long-term Cardiovascular Events Following Percutaneous Coronary Intervention.

Niwa K, Tanaka A, Funakubo H, Otsuka S, Yoshioka N, Kudo N Intern Med. 2021; 60(24):3865-3871.

PMID: 34148960 PMC: 8758441. DOI: 10.2169/internalmedicine.7336-21.

References
1.
Antman E, Hand M, Armstrong P, Bates E, Green L, Halasyamani L . 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008; 51(2):210-47. DOI: 10.1016/j.jacc.2007.10.001. View

2.
Ueeda M, Doumei T, Takaya Y, Ohnishi N, Takaishi A, Hirohata S . Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction. Heart Vessels. 2010; 26(2):145-52. DOI: 10.1007/s00380-010-0038-8. View

3.
LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View

4.
Thygesen K, Alpert J, Jaffe A, Chaitman B, White H, Katus H . Third universal definition of myocardial infarction. Circulation. 2012; 126(16):2020-35. DOI: 10.1161/CIR.0b013e31826e1058. View

5.
Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M . Association between the docosahexaenoic acid to arachidonic acid ratio and acute coronary syndrome: a multicenter observational study. BMC Cardiovasc Disord. 2016; 16(1):143. PMC: 4937597. DOI: 10.1186/s12872-016-0299-y. View